Publication
Drug Repurposing Approach Identifies a Synergistic Drug Combination of an Antifungal Agent and an Experimental Organometallic Drug for Melanoma Treatment
Publications associées (52)
Mechanism of KRAS-driven T cell infiltration in colorectal cancer
Colorectal cancer is the second-leading cause of cancer death worldwide. Early-stage disease can be detected with preventative medical screening and is treatable with surgical resection. Sixty-percent of patients, however, are diagnosed with advanced-stage ...
EPFL2023Tumor dormancy: EMT beyond invasion and metastasis
Cathrin Brisken, Hazel Margaret Quinn, Patrik Aouad
More than two-thirds of cancer-related deaths are attributable to metastases. In some tumor types metastasis can occur up to 20 years after diagnosis and successful treatment of the primary tumor, a phenomenon termed late recurrence. Metastases arise from ...
WILEY2023Discovery and Development of Hyperthermia-Enhanced Treatments for Malignant Skin and Uveal Melanomas
Melanomas are among the deadliest cancers, with a high predisposition to metastasis and a bad prognosis in their late stages. The effectiveness of current therapeutic regimens remains suboptimal, and despite initial successes, treatment resistance emerges ...
EPFL2023Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy
Monia Guidi, Nadia Terranova, Federico Amato, Daniel Abler, Olivier Michielin, Alexandre Wicky
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy but only a fraction of patients benefits from this therapy. Model-informed drug development can be used to assess prognostic and predictive clinical factors or biomark ...
2023Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth
Michele De Palma, Nadine Fournier, Stefanie Siegert, Mauro Delorenzi, Mario Leonardo Squadrito, Sina Nassiri, Pascale Anderle Pedone, Simone Ragusa, François Renevey
Stem and progenitor cells residing in the intestinal crypts drive the majority of colorectal cancers (CRCs), yet vascular contribution to this niche remains largely unexplored. Vascular endothelial growth factor A (VEGFA) is a key driver of physiological a ...
London2022The role of eosinophils in breast cancer
Eosinophils are granulocytes and belong to the innate arm of immunity. Eosinophils can be in different basal or activation states and depending on which type of activation is applied, they exert different effector functions. These multi-functional cells ha ...
EPFL2022Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity
Douglas Hanahan, Krisztian Homicsko, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz, Ksenya Shchors, Julie Laetitia Scotton
Glioblastoma (GBM) is poorly responsive to therapy and invariably lethal. One conceivable strategy to circumvent this intractability is to co-target distinctive mechanistic components of the disease, aiming to concomitantly disrupt multiple capabilities re ...
2022An autonomous microfluidic device for identification and analysis of individual clinically-relevant mammalian cells
Fabien Louis Claude Robert Jammes
Cancer represents one of the major public health challenges worldwide, representing more than 25% of all deaths in the European Union in 2014. It affects a large and growing part of the general population, with the National Cancer Institute (NCI) estimatin ...
EPFL2021Intraductal xenografts model estrogen receptor-positive (ER+) breast cancer dormancy and reveal a critical role for epithelial-mesenchymal transition (EMT) in its establishment
Compared to estrogen receptor-negative (ER-) breast cancer (BC), ER+ BC often manifests with a latent disease that recurs decades after initial diagnosis. The mechanisms governing dormancy and distant recurrence of ER+ tumors remain elusive due to the lack ...
EPFL2021Targeting LRG1 boosts immunotherapy
Michele De Palma, Amanda Waite Lund
Vascular normalization therapy has the potential to facilitate drug delivery and lymphocyte infiltration in tumors. Yet, optimal targets and dosage regimens remain elusive. In this issue of Med, O’Connor et al. show that inhibition of LRG1 stabilizes the t ...
2021